HRP20100666T1 - ANTI MIOZINSKA Va siRNA I DEPIGMENTACIJA KOŽE - Google Patents
ANTI MIOZINSKA Va siRNA I DEPIGMENTACIJA KOŽE Download PDFInfo
- Publication number
- HRP20100666T1 HRP20100666T1 HR20100666T HRP20100666T HRP20100666T1 HR P20100666 T1 HRP20100666 T1 HR P20100666T1 HR 20100666 T HR20100666 T HR 20100666T HR P20100666 T HRP20100666 T HR P20100666T HR P20100666 T1 HRP20100666 T1 HR P20100666T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- sirna
- nucleotide sequence
- sirna according
- fragment
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract 18
- 206010040825 Skin depigmentation Diseases 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 20
- 239000002773 nucleotide Substances 0.000 claims abstract 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract 8
- 239000012634 fragment Substances 0.000 claims abstract 7
- 102000003505 Myosin Human genes 0.000 claims abstract 6
- 108060008487 Myosin Proteins 0.000 claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108020005544 Antisense RNA Proteins 0.000 claims abstract 4
- 239000003184 complementary RNA Substances 0.000 claims abstract 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 3
- 230000000295 complement effect Effects 0.000 claims abstract 3
- 101150034814 F gene Proteins 0.000 claims abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091081021 Sense strand Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 230000035614 depigmentation Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003810 hyperpigmentation Effects 0.000 claims 1
- 208000000069 hyperpigmentation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002087 whitening effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0512553A FR2894582B1 (fr) | 2005-12-12 | 2005-12-12 | Sirna anti myosine va et depigmentation de la peau |
| PCT/EP2006/069618 WO2007068704A1 (fr) | 2005-12-12 | 2006-12-12 | Sirna anti myosine va et depigmentation de la peau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100666T1 true HRP20100666T1 (hr) | 2011-03-31 |
Family
ID=36617133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100666T HRP20100666T1 (hr) | 2005-12-12 | 2010-12-03 | ANTI MIOZINSKA Va siRNA I DEPIGMENTACIJA KOŽE |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7999096B2 (de) |
| EP (2) | EP1963507B1 (de) |
| JP (1) | JP2009518022A (de) |
| KR (1) | KR20080079298A (de) |
| CN (1) | CN101326286A (de) |
| AT (1) | ATE484585T1 (de) |
| AU (1) | AU2006325359A1 (de) |
| BR (1) | BRPI0619738A2 (de) |
| CA (1) | CA2632837A1 (de) |
| DE (1) | DE602006017586D1 (de) |
| DK (1) | DK1963507T3 (de) |
| ES (1) | ES2351996T3 (de) |
| FR (1) | FR2894582B1 (de) |
| HR (1) | HRP20100666T1 (de) |
| IL (1) | IL191728A0 (de) |
| MA (1) | MA30034B1 (de) |
| NO (1) | NO20083089L (de) |
| PL (1) | PL1963507T3 (de) |
| PT (1) | PT1963507E (de) |
| RU (1) | RU2008125041A (de) |
| TN (1) | TNSN08252A1 (de) |
| WO (1) | WO2007068704A1 (de) |
| ZA (1) | ZA200805739B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4981381B2 (ja) * | 2006-08-04 | 2012-07-18 | 株式会社ナリス化粧品 | 美白用皮膚外用剤 |
| EP2105145A1 (de) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide |
| JP5420669B2 (ja) * | 2008-09-10 | 2014-02-19 | エル、ベ、エム、アッシュ、ルシェルシュ | 皮膚または毛髪の色素沈着の検討または調節に有用な方法、組成物で使用するための植物抽出物、および化粧的ケアの方法 |
| EP2949752B1 (de) | 2008-09-22 | 2017-12-20 | RXi Pharmaceuticals Corporation | Selbstfreisetzende rnai-verbindungen von reduzierter grösse |
| WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
| WO2011133876A2 (en) * | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| EP2814455B1 (de) | 2012-02-13 | 2017-07-19 | Unilever N.V. | Hautaufhellende zusammensetzung |
| CN102925443A (zh) * | 2012-11-01 | 2013-02-13 | 东北师范大学 | 靶向沉默MyoⅩ的序列制备及其载体的构建 |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| CN105560635A (zh) * | 2015-09-17 | 2016-05-11 | 张名静 | 一种治疗黑色棘皮病的中药 |
| BR102018001541B1 (pt) | 2018-01-24 | 2021-05-11 | Universidade Federal Do Rio Grande Do Sul | composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência |
| JP2022541896A (ja) * | 2019-07-18 | 2022-09-28 | オリパス コーポレーション | メラノフィリンアンチセンスオリゴヌクレオチド |
| WO2021020412A1 (ja) * | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772607B1 (fr) | 1997-12-19 | 2000-02-04 | Oreal | Utilisation de derives amides d'amino phenol comme agents depigmentants |
| GB9903216D0 (en) | 1999-02-13 | 1999-04-07 | Zylepsis Ltd | Preservative compounds,compositions and methods of making and using the same |
| IL144850A0 (en) | 1999-03-22 | 2002-06-30 | Pfizer | Resorcinol derivatives |
| HN2000000033A (es) | 1999-03-22 | 2001-02-02 | Pfizer Prod Inc | Composicion de resorcinol |
| FR2804960B1 (fr) | 2000-02-11 | 2005-06-24 | Lvmh Rech | Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants |
| US7504385B2 (en) * | 2003-12-17 | 2009-03-17 | Avon Products, Inc. | si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation |
| FR2864539B1 (fr) | 2003-12-30 | 2012-10-26 | Lvmh Rech | Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee |
| EP1752536A4 (de) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | Rna-störung verursachendes polynukleotid sowie verfahren zur regulation der genexpression unter verwendung davon |
-
2005
- 2005-12-12 FR FR0512553A patent/FR2894582B1/fr not_active Expired - Fee Related
-
2006
- 2006-12-12 DK DK06830566.3T patent/DK1963507T3/da active
- 2006-12-12 RU RU2008125041/13A patent/RU2008125041A/ru not_active Application Discontinuation
- 2006-12-12 DE DE602006017586T patent/DE602006017586D1/de active Active
- 2006-12-12 KR KR1020087016595A patent/KR20080079298A/ko not_active Application Discontinuation
- 2006-12-12 EP EP06830566A patent/EP1963507B1/de active Active
- 2006-12-12 JP JP2008543854A patent/JP2009518022A/ja active Pending
- 2006-12-12 BR BRPI0619738-8A patent/BRPI0619738A2/pt not_active IP Right Cessation
- 2006-12-12 WO PCT/EP2006/069618 patent/WO2007068704A1/fr active Application Filing
- 2006-12-12 CN CNA2006800465110A patent/CN101326286A/zh active Pending
- 2006-12-12 PL PL06830566T patent/PL1963507T3/pl unknown
- 2006-12-12 AU AU2006325359A patent/AU2006325359A1/en not_active Abandoned
- 2006-12-12 CA CA002632837A patent/CA2632837A1/fr not_active Abandoned
- 2006-12-12 EP EP10172940A patent/EP2264171A1/de not_active Withdrawn
- 2006-12-12 PT PT06830566T patent/PT1963507E/pt unknown
- 2006-12-12 AT AT06830566T patent/ATE484585T1/de active
- 2006-12-12 ES ES06830566T patent/ES2351996T3/es active Active
- 2006-12-12 US US12/086,242 patent/US7999096B2/en not_active Expired - Fee Related
-
2008
- 2008-05-27 IL IL191728A patent/IL191728A0/en unknown
- 2008-06-06 MA MA31010A patent/MA30034B1/fr unknown
- 2008-06-11 TN TNP2008000252A patent/TNSN08252A1/en unknown
- 2008-07-01 ZA ZA200805739A patent/ZA200805739B/xx unknown
- 2008-07-10 NO NO20083089A patent/NO20083089L/no not_active Application Discontinuation
-
2010
- 2010-12-03 HR HR20100666T patent/HRP20100666T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2632837A1 (fr) | 2007-06-21 |
| JP2009518022A (ja) | 2009-05-07 |
| IL191728A0 (en) | 2011-08-01 |
| EP1963507A1 (de) | 2008-09-03 |
| US7999096B2 (en) | 2011-08-16 |
| AU2006325359A1 (en) | 2007-06-21 |
| DK1963507T3 (da) | 2011-01-03 |
| ES2351996T3 (es) | 2011-02-14 |
| NO20083089L (no) | 2008-07-10 |
| TNSN08252A1 (en) | 2009-10-30 |
| ZA200805739B (en) | 2009-07-29 |
| KR20080079298A (ko) | 2008-08-29 |
| FR2894582B1 (fr) | 2008-02-22 |
| DE602006017586D1 (de) | 2010-11-25 |
| AU2006325359A2 (en) | 2008-07-31 |
| CN101326286A (zh) | 2008-12-17 |
| FR2894582A1 (fr) | 2007-06-15 |
| EP1963507B1 (de) | 2010-10-13 |
| PL1963507T3 (pl) | 2011-04-29 |
| ATE484585T1 (de) | 2010-10-15 |
| PT1963507E (pt) | 2010-11-24 |
| BRPI0619738A2 (pt) | 2011-10-11 |
| RU2008125041A (ru) | 2010-01-20 |
| WO2007068704A1 (fr) | 2007-06-21 |
| MA30034B1 (fr) | 2008-12-01 |
| US20090239934A1 (en) | 2009-09-24 |
| EP2264171A1 (de) | 2010-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100666T1 (hr) | ANTI MIOZINSKA Va siRNA I DEPIGMENTACIJA KOŽE | |
| Saxena et al. | Ribozymes correctly cleave a model substrate and endogenous RNA in vivo. | |
| UA101806C2 (ru) | Одноцепочечная кольцевая рнк и способ ее получения | |
| CY1108870T1 (el) | Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους | |
| JP2001002696A (ja) | ギャップを有する２′修飾オリゴヌクレオチド | |
| JP2014527401A5 (de) | ||
| DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
| JPH06506834A (ja) | 閉鎖アンチセンス及びセンスオリゴヌクレオチドとそれらの適用 | |
| BRPI0811170B8 (pt) | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila | |
| EA200870402A1 (ru) | Фармацевтическая композиция | |
| RU2006126643A (ru) | Олигомерные соединения для модуляции bcl-2 | |
| ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
| JP2015507625A5 (de) | ||
| JP2007530431A5 (de) | ||
| JP2023521042A (ja) | 操作されたオリゴヌクレオチドを使用する標的化された阻害 | |
| IL169367A0 (en) | Defensin proteins | |
| CN105247051A (zh) | 治疗epas1相关疾病的有机组合物 | |
| DE60110244D1 (de) | Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide | |
| SE9503117D0 (sv) | Novel use of padlock probes | |
| HRP20211525T1 (hr) | Molekule sirna specifične za notch 1 | |
| Verheijen et al. | 2′, 5′-Oligoadenylate-peptide nucleic acids (2–5A-PNAs) activate RNase L | |
| JP2007517498A5 (de) | ||
| Serikov et al. | Mechanism of antisense oligonucleotide interaction with natural RNAs | |
| JP7216381B2 (ja) | Ｒｎａ作用抑制剤及びその利用 | |
| Zamaratski et al. | The 3′-modified antisense oligos promote faster hydrolysis of the target RNA by RNase H than the natural counterpart |